NCT06737146View on ClinicalTrials.gov

Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
High-grade Glioma
Interventions
DRUG

MT027 cells suspension

MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells

Trial Locations (1)

430030

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan

All Listed Sponsors
lead

Suzhou Maximum Bio-tech Co., Ltd.

INDUSTRY